Inhibrx Biosciences Insiders See $5.42m Investment Jump 66% Last Week

Inhibrx Biosciences insiders purchased shares in the last year, with the largest purchase being $1.5m by Independent Director John Kayyem at $14.23 per share. Although the stock increased by 14% last week, the company's market worth only gained 66% on their initial purchase. Insiders own 19% of the company, worth $66m, indicating a reasonable degree of alignment.

Inhibrx Biosciences (NASDAQ: INBX) has seen significant insider activity in the past year, with notable purchases and a recent stock price increase. Insiders, including Independent Director John Kayyem, have bought shares worth $1.5 million at $14.23 per share [2]. This purchase was made during the last year, coinciding with a 14% stock price increase over the past week. Despite this, the company's market worth has only gained 66% since the initial purchase, indicating a moderate alignment of insider interests with the stock's performance.

The insiders collectively own 19% of the company, valued at $66 million, suggesting a reasonable degree of alignment between their interests and those of the broader shareholder base [1]. This level of insider ownership is typically seen as a positive sign of confidence in the company's prospects.

Inhibrx Biosciences has been focused on developing targeted therapies for oncology and rare diseases through advanced protein engineering. The company's therapeutic candidate, INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein, is currently in Phase 1 clinical trials for AAT deficiency [1]. The company's stock has seen fluctuations in recent quarters, with a net loss in the first quarter of 2025, followed by a slight improvement in the second quarter [2]. The company's financial health remains a key factor for investors to consider.

The recent stock price increase is likely influenced by positive clinical trial results and strategic partnerships, such as the sale of INBRX-101 to Sanofi [1]. However, the stock's performance relative to insider purchases suggests that there is still room for growth and that investors should closely monitor the company's clinical trial data and financial results.

In summary, while insider purchases indicate a level of confidence in Inhibrx Biosciences, the stock's performance relative to these purchases suggests that investors should remain cautious and continue to monitor the company's progress in its clinical trials and financial health.

References:
[1] https://www.marketbeat.com/instant-alerts/filing-xtx-topco-ltd-makes-new-investment-in-inhibrx-biosciences-inc-nasdaqinbx-2025-08-13/
[2] https://www.stocktitan.net/news/INBX/